Chief Product Officer
BostonGene Corporation
Dr. Bagaev is a Chief Product Officer of BostonGene Corporation. Since joining BostonGene in 2016, he has led the ground-up development of several assays for research and clinical applications, culminating in the first-in-the-US approval of RNA-seq assay for gene expression and gene signatures. Moreover, his work in precision oncology has led to the development of approaches for characterizing tumors and their microenvironment, including RNA-seq deconvolution tool Kassandra, digital image analysis platforms, and AI-based integrated analysis of multiplex immunofluorescence and other multi-omics data. These advancements form the basis of BostonGene's Foundation Model of cancer and the immune system that integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners to design and de-risk trials, identify novel targets, and optimize therapeutic response prediction across all stages of development while simultaneously improving patient care through clinically integrated innovation.